众所周知，眼科手术长期以来对精度和稳定性有极高要求。视网膜膜剥离、玻璃体切除、视网膜注射等操作对 外科医生的手部控制能力提出了微米级的挑战，传统手术中难以避免的手颤和视觉–动作不一致增加了手术风 险。 眼科手术机器人的出现，为上述难题提供了全新的技术解决方案。通过高刚性的机械臂结构和精密的运动控制 算法，机器人系统能够有效滤除人手固有震颤，实现亚毫米级甚至微米级的定位稳定性。此外，手术机器人的 应用也显著提升了操作的精细度与可重复性。这不仅降低了因操作误差导致的并发症风险，也使一些以往被视 为过于复杂或风险极高的眼底手术成为可能。 近年来，随着人工智能技术，特别是以视觉-语言-动作协同为代表的具身智能（Embodied AI）的快速发 展，眼科手术机器人正迎来新一轮技术变革。 未来的机器人将不再仅仅是外科医生的"放大镜"和"稳定器"， 而是逐步具备环境感知、决策分析与自主执行能力的手术伙伴。例如，在图像识别和路径规划能力支持下，机 器人有潜力实现从入眼定位到目标区域操作的全过程自主化这种高度自主化不仅将进一步提升手术效率与一致 性，更可能为眼科手术的标准化、规模化普及开辟全新路径，尤其在医疗资源相对匮乏的地区 ...

Investment Rating - The report assigns a "Buy" rating to the company, with a target price of 14 CNY per share based on a 33X PE for the year 2025 [3][5]. Core Insights - The company has successfully acquired an 18% stake in Ruobo, an innovative enterprise in the medical robotics field, which utilizes a clear core technology framework involving AI algorithms, an industrial operating system, and high-precision servo systems [1]. - The company is strategically transforming from a materials supplier to a comprehensive service provider in the eco-friendly art space, focusing on the assembly-type integrated market opportunities both domestically and internationally [3]. - The automotive interior materials segment has seen a significant revenue increase of 35.96% year-on-year, reaching 305 million CNY in the first half of 2025, despite a declining market for main engine manufacturers [2]. Financial Summary - The company's projected revenues for 2025 are estimated at 3.218 billion CNY, with a year-on-year growth of 3.81% [4]. - The net profit attributable to the parent company is forecasted to be 126 million CNY in 2025, reflecting a growth of 25.22% compared to the previous year [4]. - The earnings per share (EPS) for 2025 is expected to be 0.41 CNY, with a corresponding PE ratio of 23.36 [4][12]. Business Segments - The construction ceramics segment, led by the subsidiary Yingpai, achieved a sales area of 2.03 million square meters in the first half of 2025, marking a 6% increase year-on-year, despite a 6% decline in revenue due to falling terminal sales prices [2]. - The company’s fireproof decorative panel business saw a revenue increase of 23.33% year-on-year, with a gross margin of 33.18% in the first half of 2025 [2].

Core Insights - The "Co-creating a New Future - China-US Local Industry Exchange Conference" was recently held in Beijing, focusing on innovation ecosystems and new opportunities for China-US industrial cooperation [1] - The event was co-hosted by the Investment Promotion Bureau of the Ministry of Commerce and the Haidian District People's Government, attracting nearly 100 representatives from both governments and the business community [1] Group 1: Innovation and Industry Strengths - Haidian District boasts significant innovation resources and industrial advantages, including top universities and research institutions such as Tsinghua University and Peking University, as well as two national laboratories and 52 key national laboratories [1] - The core digital economy industry accounts for over 50% of the region, forming a modern industrial system supported by trillion-level industrial clusters in artificial intelligence, integrated circuits, and healthcare [1] Group 2: Collaboration and Exchange - The conference featured deep exchanges among representatives from both countries, with 10 US business and political representatives discussing the business environment and cooperation opportunities in the Midwest [1] - Haidian enterprises showcased their latest achievements and collaboration needs in fields such as renewable energy, medical robotics, artificial intelligence, food, and gaming [1] - Eighteen Haidian companies displayed innovative products like robots, AI glasses, and wine, engaging in discussions with the US delegation to explore collaboration opportunities [1]

Core Viewpoint - The Jinan Precision Medicine Industrial Park is rapidly developing as a key component of the Jinan International Medical Center, providing essential infrastructure and comprehensive services to help resident companies overcome development bottlenecks and achieve rapid transformation of technological achievements [1][2]. Group 1: Company Development - Jinan Huayin Kang Medical Testing Co., Ltd. focuses on third-party medical diagnostic services and has initiated a remote pathology platform project to convert traditional glass pathology slices into digital images, enabling remote diagnosis for grassroots hospitals [1][2]. - Shandong Aopeng Intelligent Technology Co., Ltd. has achieved a significant breakthrough with its self-developed intelligent robot successfully completing an all-automated interventional surgery animal experiment, demonstrating sub-millimeter operational precision [2][3]. Group 2: Market Opportunities and Challenges - The Precision Medicine Industrial Park has facilitated the development of resident companies by coordinating support and policy assistance, leading to a 10% increase in the budget for Jinan Huayin Kang this year compared to last year [2]. - The park has organized product promotion events and established communication channels with clinical experts, which are crucial for accelerating product iteration and market entry for companies like Aopeng Intelligent [3]. Group 3: Growth Metrics - The number of registered and resident companies in the Jinan Precision Medicine Industrial Park has increased by 248% and 300% respectively this year, indicating a significant improvement in both quantity and quality of enterprises [3]. - The park focuses on providing tailored services to different types of companies, including high-end medical services, new-generation biotechnology, high-end medical devices, and digital healthcare, covering nearly 20 sub-sectors [3][4]. Group 4: Strategic Development - The park is forming a comprehensive medical industry chain with upstream and downstream connections, focusing on new areas such as cell and gene therapy, brain-machine interfaces, and AI healthcare [4]. - By creating public technology platforms and integrating market resources, the park is enhancing its "precision" role and effectiveness, becoming a vital engine for the high-quality development of the Jinan International Medical Center [4].

蛇形臂单孔机器人具备多维度操作能力，可在狭小空间内实现稳定、精细的组织分离与缝合。 "我们的手术机器人在胸外科的肺叶切除、妇科的肿瘤切除等手术均能开展，目前已在内地60多家三甲 医院完成上千例手术。"该机器人产品临床应用工程师寿鹤君介绍，该公司的机器人不仅能避免器械在 腹腔内"打架"，还能让器械操作方向与医生手部动作保持一致，缩短主刀医生的学习周期。 寿鹤君表示，目前行业规范化体系已逐步完善，官方针对手术机器人的临床应用、医生培训等制定了明 确标准，企业也在通过专利布局构建核心竞争力，"未来手术机器人将朝着精细化、小型化、远程化方 向发展，尤其是结合AI技术实现远程手术，有望打破地域医疗资源壁垒"。 手术机器人技术工程师余家锋表示，中国国产机器人在技术上已实现"精度达标、全术式覆盖"，且行业 正通过协会推广、临床案例共享等方式加速医生接受度。 (经济观察)中国医疗机器人加速覆盖多诊疗场景 中新社广州9月19日电 (记者 蔡敏婕)2025第五届广州精准医学博览会(医疗机器人专场)19日在广州开 幕。随着人工智能、智能传感等技术的发展与应用，中国医疗机器人加速覆盖多诊疗场景，从本届博览 会可见一斑。 9月19日， ...

近日，成都市凯瑞医疗科技有限公司（以下简称"凯瑞医疗"）宣布完成Pre-A+轮融资。据了解，本轮投资由泸州老窖集团旗下华西证券全资直投 公司——华西银峰投资有限责任公司（以下简称"华西银峰"）独家投资。值得注意的是，这是继上一轮由泸州市双港实业投资发展有限公司对其 投资数千万元后，泸州国资体系在短时间内对凯瑞医疗进行的追加投资，完成本轮融资后，公司估值已超过2.5亿元。 凯瑞医疗创立于2022年，是多模态类人形医疗机器人企业，在采血、超声、AI视觉领域均有布局产品，核心产品是智能采血机器人（M系类）。据悉，公司 首款产品M1Pro已完成临床试验，正进行三类医疗器械注册许可证的申请流程，此外便携式采血机器人（M1mini）也已进入研发周期。 基于行业痛点和市场机遇 采血全流程仅需约90秒 血液检测作为临床诊断的标准，为超过70%的医疗决策提供关键依据，这使得采血成为全球医疗系统中最高频的刚需操作之一。但同时，面对全球2000多亿 元的庞大市场空间，当前采血领域却呈现出明显的供需失衡：一方面，临床面临婴幼儿、老年人群等特殊血管穿刺的痛点；另一方面，行业仍完全依赖人工 操作，缺乏真正成熟的产品，智能化渗透率几乎为零 ...

Group 1 - Chengdu Kairui Medical Technology Co., Ltd. has completed a Pre-A+ round of financing, with a valuation exceeding 250 million yuan after this round [1] - The investment was exclusively made by Huaxi Silver Peak Investment Co., Ltd., a wholly-owned subsidiary of Luzhou Laojiao Group [1] - Kairui Medical focuses on multimodal humanoid medical robots, addressing pain points in repetitive and high-intensity tasks in the medical field [1][3] Group 2 - The company's core product is the intelligent blood collection robot (M series), with the first product M1Pro having completed clinical trials and currently undergoing the registration process for Class III medical devices [1][3] - The portable blood collection robot (M1mini) is in the research and development phase, targeting a significant market space of over 200 billion yuan globally [3][5] Group 3 - Kairui Medical's blood collection robots aim to reduce pain and improve efficiency in blood collection, with a full process time of approximately 90 seconds [3][5] - The robots utilize dual infrared and ultrasound technology to enhance precision in blood vessel targeting, achieving sub-millimeter accuracy [5][6] Group 4 - The company is expanding its AI vision technology to various applications, including a collaboration with Beijing Scar Hospital to develop the S1 scar intelligent detection system [5][6] - The S1 system assists in monitoring scar treatment through multi-dimensional quantitative assessments [5] Group 5 - The recent financing will primarily be used for establishing clinical demonstration centers and accelerating data accumulation and product optimization [5][6] - Kairui Medical plans to promote a new medical scenario combining self-service blood collection and rapid report generation [5][6] Group 6 - The company aims to address public concerns about robot-assisted blood collection by enhancing user experience and comfort, including the development of a "pain-free needle" [6] - Kairui Medical emphasizes precision as a core technology, showcasing strong clinical adaptability across different age groups [6][7] Group 7 - Huaxi Silver Peak expressed confidence in the potential of intelligent puncture technology in medical automation, highlighting its social value and commercial potential [7]

更令人眼前一亮的是，本届赛事首次采用"真人＋AI机器人"双主持组合，人机配合流畅自然，成为全场 焦点。而在颁奖环节，机器人礼仪员精准无误地递送奖牌与证书，动作稳定、配合默契。 9月14日，在2025年中国国际服务贸易交易会召开之际，由北京市卫生健康委员会指导，北京市医院管 理中心主办的第七届科技创新大赛（机器人医疗应用场景）决赛同期举办。本届大赛围绕服贸会"数智 领航，服贸焕新"的年度主题，聚焦全球医疗科技前沿领域，展现北京作为国际科技创新中心在智慧医 疗方面的领先水平和使命担当。 北京市卫生健康委党委书记钟东波在致辞中强调，医疗机器人，特别是手术机器人已成为衡量一个国家 医学科技创新水平的重要标志。医疗系统要积极参与医疗机器人研发应用，一是要拥抱创新，充分释放 医学科技的临床价值和健康价值；二是要坚守价值，科技创新必须坚持科技向善、以人为本，落实人民 至上、生命至上的价值观；三是要加强协作，机器人研发需要从临床需求出发，加强医工结合与协同； 四是要完善政策，完善融资、定价、医保支付等政策，大大释放技术潜力；五是要勇担责任，首都医疗 机构要做到四个率先，率先提出临床需求、率先联合研发、率先提供验证服务和数据支 ...

针对这些痛点，长木谷数智骨科手术室构建了从数据管理、手术规划、机器人辅助执行、术后评估到 5G远程协作的一体化闭环系统。该平台实现了术前智能诊断与精准规划、术中实时导航与机器人辅助 操作、术后量化评估与远程互联的全链路覆盖，显著提升手术精准度和安全性，降低辐射和对人工经验 的依赖。 此次亮相的AI+手术机器人5G远程诊疗一体化平台，在真正意义上打破了传统骨科手术各环节分离的局 限，推动了中国顶尖骨科技术"走出去"，也开创了医疗服贸的新模式。 北京商报讯(记者王寅浩实习记者宋雨盈)在2025年中国国际服务贸易交易会(以下简称"服贸会")的健康 卫生服务专题展区，医疗机器人的精彩展示成为关注的焦点。9月13日，记者在服贸会现场看到，长木 谷、西门子医疗、GE医疗、联影医疗等国内外领军企业纷纷亮相，带来了他们的最新创新成果。其 中，长木谷首次展出其创新产品——"AI+手术机器人5G远程诊疗一体化平台"，该平台通过5G远程系统 实现跨区域，无国界的手术实时直播、手术指导、跨国会诊，让中国方案可以服务全球患者。 据长木谷相关人员介绍，传统骨科手术室长期面临多项瓶颈：患者信息依赖纸质媒介，易出错且效率低 下；手术规划、执 ...

针对这些痛点，长木谷数智骨科手术室构建了从数据管理、手术规划、机器人辅助执行、术后评估到 5G远程协作的一体化闭环系统。该平台实现了术前智能诊断与精准规划、术中实时导航与机器人辅助 操作、术后量化评估与远程互联的全链路覆盖，显著提升手术精准度和安全性，降低辐射和对人工经验 的依赖。 此次亮相的AI+手术机器人5G远程诊疗一体化平台，在真正意义上打破了传统骨科手术各环节分离的局 限，推动了中国顶尖骨科技术"走出去"，也开创了医疗服贸的新模式。 北京商报讯（记者 王寅浩 实习记者 宋雨盈）在2025年中国国际服务贸易交易会（以下简称"服贸会"） 的健康卫生服务专题展区，医疗机器人的精彩展示成为关注的焦点。9月13日，记者在服贸会现场看 到，长木谷、西门子医疗、GE医疗、联影医疗等国内外领军企业纷纷亮相，带来了他们的最新创新成 果。其中，长木谷首次展出其创新产品——"AI+手术机器人5G远程诊疗一体化平台"，该平台通过5G远 程系统实现跨区域，无国界的手术实时直播、手术指导、跨国会诊，让中国方案可以服务全球患者。 据长木谷相关人员介绍，传统骨科手术室长期面临多项瓶颈：患者信息依赖纸质媒介，易出错且效率低 下；手术规 ...